Cambium Bio (ASX:CMB) entered into a memorandum of understanding with Benta, a French pharmaceutical company, to establish a strategic partnership to develop and commercialize Elate Ocular for dry eye disease in Europe and the Middle East, according to a Friday Australian bourse filing.
The company said the partnership will provide access to major European and Middle Eastern markets. Under the deal, Benta will facilitate exchanges with regulators in France and Europe, the Middle East, and Africa.
The company's shares rose past 4% in recent Friday trade.